Inspire price buffeted again with negative trial data

Date March 15, 2010

For Inspire Pharmaceuticals the news today that AzaSite had failed phase II trials to treat blepharitis must have had them crying the blues. The company had recovered all the losses suffered in January after it announced its dry-eye candidate Prolacria had failed a fourth phase III trial, only to have its shares drop again on the AzaSite news today (Inspire will be shedding tears on Prolacria failure, January 25, 2010).

Whilst Inspire has the promise of bringing to market a bigger-selling product in the guise of its cystic fibrosis treatment INS37217 Respiratory, AzaSite, currently indicated for bacterial conjunctivitis, is its chief moneymaker for the immediate future. As such, adding an indication that one analyst estimated to be worth $56.7m a year at peak in 2018 would have been welcome in the North Carolina company’s efforts to develop INS37217 and other products in its pipeline.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd